



Esperion Therapeutics, Inc.
Investor Relations Department
3891 Rancho Drive
Suite 150
Ann Arbor, MI 48108
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ESPR

Last Trade:	33.11
Trade Time:	3:45 PM ET May 25, 2017
Change:	-0.08 (-0.241%)
Day Range	32.89 - 33.79
52-Week Range	9.40 - 48.21
Volume	192,998


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion Therapeutics is passionately committed to developing and commercializing complementary, oral therapies for patients and physicians globally that could potentially significantly reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia inadequately treated with current lipid-modifying therapies. Bempedoic acid, Esperion-discovered and developed, brings a targeted mechanism of action to the space that could potentially address unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly".

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 22, 2017
[Esperion Provides Update on Common Stock Trading Activity](#)
- May 19, 2017
[Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)
- May 18, 2017
[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- May 12, 2017
[Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference](#)
- May 4, 2017
[Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Feb 22, 2017
[Annual Report \(10-K\)](#)
- Mar 6, 2017
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016
[Quarterly Report \(10-Q\)](#)